Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
April 10, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The U.S. general fertility rate fell to a record low of 53.1 births per 1,000 women ages 15–44 in 2025, according to provisional CDC data — continuing a decline that began in 2007 and has now persisted through six straight years of flat births (~3.6 million annually)
  • The total fertility rate — the average number of children a woman would have over her lifetime at current rates — dropped to 1.57 in 2025, well below the 2.1 replacement level; the U.S. population will eventually shrink without sustained immigration if this trend continues
  • For the first time in U.S. history, birthrates for women in their late 30s exceeded those for women in their early 20s — a structural shift reflecting delayed parenthood driven by financial uncertainty, relationship instability, and political climate concerns
  • The teen birthrate fell 7% in 2025, extending a decades-long decline; since 2007, the birthrate for 15–19-year-olds has fallen 72%, while births over deaths now produce only a half-million net surplus annually — a surplus Census projects will disappear within a decade

What Happened?

New federal data from the CDC shows that America’s fertility rate fell to a record low in 2025 for the sixth consecutive year of flat total births. The general fertility rate — births per 1,000 women ages 15 to 44 — reached 53.1, its lowest point on record. The total fertility rate dropped to 1.57 births per woman, a WSJ calculation shows, significantly below the 2.1 replacement level required for a population to sustain itself without immigration. A historic milestone was crossed in 2025: for the first time, birthrates for women in their late 30s exceeded those of women in their early 20s, reflecting the long-running shift toward delayed parenthood across generations of American women.

Why It Matters?

The fertility decline is not merely a demographic abstraction — it has direct implications for the U.S. economy, retirement systems, and the labor force over the next two to three decades. Flat births and a rising number of deaths are already shrinking the natural population surplus: the U.S. recorded just over 500,000 more births than deaths in 2025. Census Bureau and CBO projections suggest this surplus will disappear within the next decade. After that, population growth — and with it, the labor force, tax base, and economic dynamism that underpin Social Security and Medicare — will depend entirely on immigration. Demographers note that many women still want children but are waiting until financial and relational conditions feel stable enough, suggesting the gap between desired and actual fertility is structural and policy-amenable, not purely cultural.

What’s Next?

The U.S. fertility rate, while at a record low, remains higher than in many other developed nations — the UN estimates more than half of all countries are already below replacement level globally. But the gap is narrowing, and the U.S. no longer has a meaningful demographic edge over peers. Policy levers that other countries have tried — paid family leave, childcare subsidies, child tax credits — have produced mixed results in shifting fertility rates. The more immediate policy question is immigration: the same restrictionist impulses that have driven recent U.S. immigration enforcement could, if sustained, eliminate the demographic safety valve just as natural population growth runs out. How Washington navigates that tension over the next decade may be one of the most consequential long-run policy choices the country faces.

Source: The Wall Street Journal

Previous Post

Anthropic’s New AI Model Is So Dangerous Bessent and Powell Called an Emergency Meeting With Bank CEOs

Next Post

The ‘Busan Freeze’: How Trump Quietly Abandoned His Tough-on-China Playbook

Recommended For You

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
1 day ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
5 days ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
7 days ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
1 week ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
3 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
3 weeks ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
4 weeks ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more

Nvidia Partners With Abridge to Build an AI Model Trained on Real Doctor-Patient Conversations

by Team Lumida
1 month ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia and AI medical note-taking startup Abridge are jointly developing a clinical AI model trained on de-identified doctor-patient conversations, using Nvidia's open Nemotron models as a base —...

Read more

Nearly 90% of Americans Have It and Don’t Know It: First Guidelines Issued for CKM Syndrome

by Team Lumida
1 month ago
people holding us a flag during daytime

The American Heart Association and three major medical societies published the first clinical guidelines for cardiovascular-kidney-metabolic syndrome — a cluster of interconnected conditions tied to excess body fat...

Read more

Employers Are Slashing GLP-1 Coverage as Costs Spiral — And Some Are Adding Weigh-Ins to Keep It

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

More than a quarter of large companies are adding new criteria for GLP-1 weight-loss coverage while 11% are dropping it altogether, as drug costs balloon and employers struggle...

Read more
Next Post
China’s Bold Economic Moves: What You Need to Know Now

The 'Busan Freeze': How Trump Quietly Abandoned His Tough-on-China Playbook

White House, Washington DC

White House Sent Staff-Wide Email Warning Against Insider Trading on Iran War Bets

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

US Job Openings Surge to 7.77 Million in May, Led by Hospitality Sector

US Job Openings Surge to 7.77 Million in May, Led by Hospitality Sector

July 2, 2025
white paper with green line

Why Short Sellers Are Abandoning European Real Estate Stocks Now

September 12, 2024
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

The Man Who Attacked OpenAI’s HQ Had Talked About ‘Luigi-ing Tech CEOs’ Months Before

April 16, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018